GH Research (GHRS) Competitors $11.06 -1.19 (-9.71%) Closing price 04:00 PM EasternExtended Trading$11.04 -0.02 (-0.14%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. MIRM, GMTX, BLTE, ARWR, CGON, HRMY, ARQT, JANX, TVTX, and AGIOShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Belite Bio (BLTE), Arrowhead Pharmaceuticals (ARWR), CG Oncology (CGON), Harmony Biosciences (HRMY), Arcutis Biotherapeutics (ARQT), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Mirum Pharmaceuticals Gemini Therapeutics Belite Bio Arrowhead Pharmaceuticals CG Oncology Harmony Biosciences Arcutis Biotherapeutics Janux Therapeutics Travere Therapeutics Agios Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership. Which has more risk & volatility, MIRM or GHRS? Mirum Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Do insiders and institutionals hold more shares of MIRM or GHRS? 56.9% of GH Research shares are held by institutional investors. 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend MIRM or GHRS? Mirum Pharmaceuticals currently has a consensus target price of $58.20, suggesting a potential upside of 26.14%. GH Research has a consensus target price of $30.86, suggesting a potential upside of 169.97%. Given GH Research's higher possible upside, analysts plainly believe GH Research is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MIRM or GHRS more profitable? GH Research has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -31.69%. GH Research's return on equity of -20.29% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-31.69% -41.22% -14.81% GH Research N/A -20.29%-19.49% Does the MarketBeat Community prefer MIRM or GHRS? Mirum Pharmaceuticals received 102 more outperform votes than GH Research when rated by MarketBeat users. However, 76.92% of users gave GH Research an outperform vote while only 75.86% of users gave Mirum Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% GH ResearchOutperform Votes3076.92% Underperform Votes923.08% Which has better valuation and earnings, MIRM or GHRS? GH Research has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M6.71-$163.41M-$1.85-24.94GH ResearchN/AN/A-$35.59M-$0.75-15.24 Does the media prefer MIRM or GHRS? In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 2 mentions for GH Research. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat GH Research's score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMirum Pharmaceuticals and GH Research tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$594.68M$6.95B$5.64B$7.85BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-14.477.1823.1418.69Price / SalesN/A223.91389.3791.52Price / CashN/A65.6738.1634.64Price / BookN/A6.406.894.24Net Income-$35.59M$142.12M$3.20B$247.06M7 Day Performance-8.56%-4.42%-2.61%-1.91%1 Month Performance12.83%-6.85%1.89%-5.51%1 Year Performance7.22%-8.53%9.97%-0.57% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research2.4758 of 5 stars$11.06-9.7%$30.86+179.0%+14.4%$575.43MN/A-14.0010MIRMMirum Pharmaceuticals4.3574 of 5 stars$45.15+2.0%$58.20+28.9%+83.4%$2.21B$336.89M-22.35140GMTXGemini TherapeuticsN/A$51.02-2.7%N/A-13.0%$2.21BN/A-51.0230Positive NewsBLTEBelite Bio2.1399 of 5 stars$67.81+0.5%$96.33+42.1%+67.4%$2.16BN/A-61.0910Analyst ForecastARWRArrowhead Pharmaceuticals3.4377 of 5 stars$15.60+1.6%$41.44+165.7%-51.9%$2.14B$2.50M-3.02400CGONCG Oncology1.2223 of 5 stars$27.67-0.5%$63.88+130.8%-34.3%$2.10B$684,000.000.0061Earnings ReportAnalyst ForecastNews CoverageHRMYHarmony Biosciences4.4516 of 5 stars$34.32+4.9%$53.11+54.8%-0.5%$1.97B$714.73M16.27200ARQTArcutis Biotherapeutics2.5397 of 5 stars$16.42+12.3%$18.80+14.5%+67.8%$1.95B$196.54M-9.17150Short Interest ↓Positive NewsHigh Trading VolumeJANXJanux Therapeutics2.6302 of 5 stars$31.51+2.7%$92.44+193.4%-21.5%$1.86B$10.59M-26.9330Positive NewsTVTXTravere Therapeutics2.7735 of 5 stars$20.87+5.8%$30.62+46.7%+165.6%$1.85B$233.18M-5.09460News CoveragePositive NewsAGIOAgios Pharmaceuticals4.3476 of 5 stars$31.99+3.4%$56.57+76.8%+5.9%$1.83B$36.50M2.82390Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies Mirum Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Belite Bio Alternatives Arrowhead Pharmaceuticals Alternatives CG Oncology Alternatives Harmony Biosciences Alternatives Arcutis Biotherapeutics Alternatives Janux Therapeutics Alternatives Travere Therapeutics Alternatives Agios Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GHRS Stock Free GHRS Stock Alerts